b'Pursuing ourobjectivescommunity. This ensures that the research we fund is of the high-est international standards and avoids conflict of interest. Over the past year, Genome Canada recruited 138 reviewers from 11 countries. Genome Canadas board of directors makes the final decision on which applications to fund, based on recommenda-tions received from the international panel of reviewers.Large-scale T he foundation of Genome Canadas research portfolio is the Large Scale Applied Research Project Program, research projects whichsupportsambitious,interdisciplinaryapplied research aimed at putting genomics into the hands of those who will use it. These projects are selected via sector-based competitions involving a highly-competitive peer review process. Each project must include an integrated GE3LS component to help promote the use of genomic-based research and innovationin particular to investigate key factors that may facilitate or hinder the effective translation of research and the uptake of genomic-based applications. Finally, these projects are co-funded by provincial governments, industry or other users and partner organizations at a rate of at least 1:1 versus federal dollars.This year saw the launch of 15 successful projects from the 2017 LSARP Competition in Genomics and Precision Health. These projects, co-funded with CIHRare expected to improve health outcomes and/or enhance the cost-effectiveness of the health-care system. A broad range of projects and research leaders were funded (a full list and descriptions are here). Projects include:Dr. Laura Arbour (University of British Columbia), Dr. Nadine Caron (University of British Columbia), Dr. Wyeth W. Wasserman (BC Childrens Hospital Research Institute). The project Silent Genomes is designed to address barriers to the growing genomic healthdividebetweenIndigenouspopulationsandother Canadians.Dr. Ian Lewis (University of Calgary) and Dr. Deirdre Church (Cal- gary Laboratory Services). This project is designed to reduce the global burden of infectious diseases and anti-microbial resistance through a new Precision Infection Management strategy designed to match appropriate antibiotic use with individual patients.Dr. Alain Stintzi (University of Ottawa) and Dr. David Mack (Childrens Hospital of Eastern Ontario). A project designed to identify, characterize and quantify the gut microbiome associ-ated with treatments for Inflammatory Bowel Disease (IBD) in order to personalize treatment plans.Dr. Nada Jabado (Research Institute of the McGill University Health Centre), Dr. Michael Taylor (SickKids), Dr. Jacek Majewski (McGill University). This project will build on early work that pediatric brain tumours are driven by mutations in brain devel-16 Genome Canada Annual Report 2018-19'